Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Down syndrome (DS) is associated with cognitive impairments, but the precise molecular mechanisms remain elusive.
• The gene dosage hypothesis suggests that overexpression of specific genes in DS can lead to widespread functional deficits.
• Regulatory mechanisms, such as RNA splicing, are implicated but not fully understood in DS pathogenesis.

Purpose of the Study:

• To investigate the role of RNA splicing defects in Down syndrome brain dysfunction.
• To determine if Dyrk1A, a gene overexpressed in DS, contributes to splicing abnormalities.
• To explore potential therapeutic strategies targeting splicing in early DS development.

Main Methods:

• Analysis of fetal Down syndrome brain samples.
• Utilizing engineered mouse models with partial trisomy (Ts65Dn) or Dyrk1A overexpression.
• Investigating splicing patterns of key synaptic transcripts (e.g., BDNF, neuroligin, acetylcholinesterase variants).
• Examining nuclear speckle structure and SR protein phosphorylation in neuronal models.

Main Results:

• Down syndrome brains and Dyrk1A-overexpressing models exhibit modest but amplified changes in splicing machinery.
• Specific alterations in splicing of TRKB, neuroligin, and acetylcholinesterase (AChE) transcripts were observed, impacting synaptic protein function.
• Dyrk1A overexpression was sufficient to induce changes in AChE splicing and affect neuronal nuclear speckles and SR protein phosphorylation.
• DS-like splicing defects were identified in Dyrk1A-overexpressing mice.

Conclusions:

• Impaired RNA splicing, driven by Dyrk1A overexpression, is a significant factor in Down syndrome brain dysfunction.
• These splicing alterations affect critical synaptic genes, potentially contributing to cognitive deficits.
• Restoring balanced splicing early in development may represent a promising therapeutic avenue for Down syndrome.